5730536A07Rik Activators
5730536A07Rik Activators delineates a specific category of chemical compounds that can enhance the expression of the gene represented by the identifier 5730536A07Rik. The discovery of such activators typically commences with high-throughput screening (HTS), a process capable of evaluating many thousands of compounds for their ability to modulate gene expression. Central to HTS is the use of a reporter gene assay, wherein a detectable reporter gene product is linked to the promoter region of the 5730536A07Rik gene. When cells harboring this reporter construct are exposed to a diverse chemical library, the activator compounds that effectively increase promoter activity will induce a corresponding increase in reporter gene expression. This increase is measurable using various detection methods depending on whether the reporter system is based on fluorescence, luminescence, or another quantifiable signal. The signal intensity correlates directly with the compound's ability to activate the gene, and those compounds that cause a conspicuous enhancement of the signal are singled out for further validation as activators of the 5730536A07Rik gene.
After the initial identification of promising compounds, the validation phase is critical to confirm their role as 5730536A07Rik activators. Quantitative PCR (qPCR) is employed to quantify the levels of mRNA corresponding to the 5730536A07Rik gene. An elevation in mRNA levels as determined by qPCR is indicative that the compound can stimulate gene transcription. Moreover, to confirm that the mRNA upregulation leads to an increase in the actual protein, Western blot analysis is performed. An intensification of the protein bands on the Western blot in comparison to untreated controls confirms that the compound can promote the processing of the gene's transcription into a functional protein. This combination of qPCR and Western blot analysis provides a comprehensive and reliable means to verify the activity of compounds as activators of the 5730536A07Rik gene, ensuring that the observed upregulation of gene expression is substantial and leads to an actual increase in the protein encoded by the gene.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC), which could lead to the phosphorylation of downstream proteins. If the "5730536A07Rik" protein is a PKC substrate or is involved in PKC pathway, this activation could enhance its activity. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin is a calcium ionophore that increases intracellular calcium levels. Calcium signaling often results in the activation of calcium-dependent kinases, such as calmodulin-dependent kinase (CaMK). If "5730536A07Rik" is influenced by CaMK, ionomycin may indirectly enhance its activity. | ||||||
D-erythro-Sphingosine-1-phosphate | 26993-30-6 | sc-201383 sc-201383D sc-201383A sc-201383B sc-201383C | 1 mg 2 mg 5 mg 10 mg 25 mg | $165.00 $322.00 $570.00 $907.00 $1727.00 | 7 | |
Sphingosine-1-phosphate (S1P) is a bioactive lipid that activates S1P receptors, leading to downstream signaling effects, including those mediated by MAPK/ERK pathway. If "5730536A07Rik" is part of this pathway, S1P could indirectly enhance its activity through this signaling cascade. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG is a polyphenol that has been shown to inhibit certain protein kinases. If "5730536A07Rik" is negatively regulated by such kinases, EGCG could result in an indirect enhancement of "5730536A07Rik" by lifting this inhibition. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is an inhibitor of PI3K. By inhibiting PI3K, it may lead to altered signaling through the AKT pathway. If "5730536A07Rik" is activated by pathways downstream of AKT, LY294002 could indirectly enhance the activity of "5730536A07Rik" by affecting these pathways. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is an inhibitor of MEK1/2, enzymes in the MAPK pathway. By inhibiting MEK1/2, U0126 could shift cellular signaling to compensate, which might enhance pathways that activate "5730536A07Rik", if it is involved in MAPK-regulated processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a specific inhibitor of p38 MAPK. Inhibition of p38 MAPK can alter the cellular stress response and potentially enhance signaling pathways that activate "5730536A07Rik", if it is associated with these pathways. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 is an ionophore that increases intracellular calcium levels. This can activate calcium-dependent signaling mechanisms. If "5730536A07Rik" is part of or regulated by calcium-dependent pathways, A23187 could enhance its activity. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Thapsigargin is a SERCA pump inhibitor, which leads to an increase in intracellular calcium levels. Elevated calcium may activate calcium-dependent proteins or pathways that could potentially enhance the activity of "5730536A07Rik". | ||||||